70
Participants
Start Date
January 31, 2023
Primary Completion Date
July 31, 2028
Study Completion Date
July 31, 2028
Gilteritinib
Oral
Venetoclax
Oral
Azacitidine
Subcutaneous injection or intravenous infusion
RECRUITING
Weill Cornell Medical College, New York
RECRUITING
Motefiore-Einstein Center for Cancer Care, The Bronx
RECRUITING
Roswell Park Cancer Institute, Buffalo
ACTIVE_NOT_RECRUITING
University of Pennsylvania-Abramson CCC-Dept. of Hem Onc, Philadelphia
RECRUITING
Thomas Jefferson University Hospital, Philadelphia
RECRUITING
University of Maryland, Baltimore
RECRUITING
Johns Hopkins University, Baltimore
RECRUITING
Novant Health, Winston-Salem
RECRUITING
Memorial Cancer Institute, Pembroke Pines
RECRUITING
Ohio State University, Columbus
RECRUITING
The Medical College of Wisconsin- Froedtert Hospital, Milwaukee
RECRUITING
University of Chicago, Chicago
RECRUITING
Robert H. Lurie Comprehensive Cancer Center, Chicago
RECRUITING
The University of Texas MD, Houston
RECRUITING
Sarah Cannon Research Institute, Denver
RECRUITING
UCLA Medical Center, Los Angeles
RECRUITING
City of Hope Nat'l Medical Center, Duarte
RECRUITING
Univ. of California - Irvine, Irvine
RECRUITING
Oregon Health and Science University, Portland
RECRUITING
Massachusetts General Hospital, Boston
Astellas Pharma Global Development, Inc.
INDUSTRY